TRPC6 and heart disorder: The Kruskal–Wallis-test suggested that this might be a statistically significant difference between the body donors (p < 0.001, Figure 5A), and it was noted that the donors with macro- and microscopically more severe heart disease (Donor 2 and Donor 3; for details see Table 1) had less TRPC6-immunoreactive myocardial area overall (both < 65%) compared to the remaining 3 donors (mainly moderate coronary heart disease, all > 72%).